Advertisement

Analytical and Bioanalytical Chemistry

, Volume 411, Issue 2, pp 395–402 | Cite as

Liquid chromatography-tandem mass spectrometry analysis of 17-hydroxyprogesterone in dried blood spots revealed matrix effect on immunoassay

  • Liqiao Han
  • Norma P. Tavakoli
  • Mark Morrissey
  • David C. Spink
  • Zhimin (Tim) CaoEmail author
Research Paper

Abstract

Immunoassays for measuring 17-hydroxyprogesterone (17-OHP) produce high rates of false positives that impact the identification of congenital adrenal hyperplasia (CAH) in neonates. A confirmatory test with high analytical specificity employing liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology is needed in newborn screening for CAH. 17-OHP and cortisol were extracted from dried blood spot (DBS) samples, resolved on a C18 column, and measured using tandem mass spectrometry. The results were compared with those determined using the AutoDELFIA immunoassay. The LC-MS/MS method had a limit of quantitation of 10.0 and 5.0 ng/mL for 17-OHP and cortisol, respectively. The method characteristics showed coefficient variation (%CV) ≤ 11.9% for both 17-OHP and cortisol, recoveries ranging from 83.1 to 101.5% for 17-OHP and from 95.1 to 102.8% for cortisol, and linearity with R2 = 0.9994 for 17-OHP and R2 = 0.9996 for cortisol, clinical sensitivity of 100.0% and a specificity of 96.4% as obtained by receiver operating characteristic analysis on 45 patient samples when 17-OHP > 39.1 ng/mL was selected as the cutoff value. Comparison between the LC-MS/MS and the AutoDELFIA immunoassay methods revealed a poor correlation for patient DBS samples (R2 = 0.6784); however, an excellent correlation was obtained for QC and proficiency test (PT) DBS samples (R2 = 0.9797). The LC-MS/MS method produced reliable results for 17-OHP and cortisol for the diagnosis of CAH. The AutoDELFIA immunoassay appears to be subject to matrix effects in the analysis for 17-OHP in DBS patient samples. The DBS samples of non-patient origin may not be suitable for assessing analytical accuracy of immunoassays.

Keywords

Newborn screening Congenital adrenal hyperplasia 17-hydroxyprogesterone Cortisol Mass spectrometry 

Abbreviations

17-OHP

17-Hydroxyprogesterone

ACN

Acetonitrile

CAH

Congenital adrenal hyperplasia

CDC

Centers for Disease Control and Prevention

DBS

Dried blood spot

LC-MS/MS

Liquid chromatography-tandem mass spectrometry

LoD

Limit of detection

LoQ

Limit of quantitation

NYS-NBS

New York State Newborn Screening

PT

Proficiency test

ROC

Receiver operating characteristic

Notes

Acknowledgements

We thank the National Natural Science Foundation of China (grant no. 81572088 and 81601861) for supporting Liqiao Han in performing the study at Wadsworth Center, New York State Department of Health.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Consent was obtained from the participants, who voluntarily donated whole blood for preparation of the control and calibrators materials. All other DBS samples were de-identified for patient information prior to receipt for analysis of the study. This study was approved by the Institutional Review Board of the New York State Department of Health.

References

  1. 1.
    Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4133–60.CrossRefGoogle Scholar
  2. 2.
    El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390:2194–10.CrossRefGoogle Scholar
  3. 3.
    Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Pediatr Clin N Am. 2011;58:1281–300.CrossRefGoogle Scholar
  4. 4.
    De Jesús VR, Mei JV, Cordovado SK, Cuthbert CD. The Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention: thirty-five year experience assuring newborn screening laboratory quality. Int J Neonatal Screen. 2015;1:13–26.CrossRefGoogle Scholar
  5. 5.
    Pearce M, DeMartino L, McMahon R, Hamel B, Maloney B, Stansfield DM, et al. Newborn screening for congenital adrenal hyperplasia in New York State. Mol Genet Metab Rep. 2016;7:1–7.CrossRefGoogle Scholar
  6. 6.
    Nordenstrom A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001;108:E68.CrossRefGoogle Scholar
  7. 7.
    Etter ML, Eichhorst J, Lehotay DC. Clinical determination of 17-hydroxyprogesterone in serum by LC-MS/MS: comparison to Coat-A-Count RIA method. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;840:69–74.CrossRefGoogle Scholar
  8. 8.
    National Newborn Screening Report 2000. Chapter 9. Congenital adrenal hyperplasia. http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/resources/newborn/00/2000Report.pdf. Accessed 17 Aug 2018.
  9. 9.
    Wong T, Shackleton CH, Covey TR, Ellis G. Identification of the steroids in neonatal plasma that interfere with 17α-hydroxyprogesterone radioimmunoassays. Clin Chem. 1992;38:1830–7.Google Scholar
  10. 10.
    Makela SK, Ellis G. Nonspecificity of a direct 17alpha-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin Chem. 1988;34:2070–5.Google Scholar
  11. 11.
    Parlak M, Ellidağ HY, Türkkahraman D. High-dose hook effect in 17-hydroxyprogesterone assay in a patient with 21-hydroxylase deficiency. J Clin Res Pediatr Endocrinol. 2015;7:329–32.CrossRefGoogle Scholar
  12. 12.
    Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, Małunowicz EM, Wójcicka A, Miśkiewicz P, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Clin Endocrinol. 2016;84:23–9.CrossRefGoogle Scholar
  13. 13.
    Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50:621–5.CrossRefGoogle Scholar
  14. 14.
    Rossi C, Calton L, Hammond G, Brown HA, Wallace AM, Sacchetta P, et al. Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2010;411:222–8.CrossRefGoogle Scholar
  15. 15.
    Fingerhut R. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values. Steroids. 2009;74:662–5.CrossRefGoogle Scholar
  16. 16.
    Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, Schulze A, et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2004;89:3687–93.CrossRefGoogle Scholar
  17. 17.
    CDC Newborn Screening Quality Assurance Program, 2017 Quality Control Program Report. https://www.cdc.gov/labstandards/pdf/nsqap/nsqap_2017_qcset1_report.pdf. Accessed 17 Aug 2018.
  18. 18.
    Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009;66:230–5.CrossRefGoogle Scholar
  19. 19.
    Magnisali P, Chalioti MB, Livadara T, Mataragas M, Paliatsiou S, Malamitsi-Puchner A, et al. Simultaneous quantification of 17α-OH progesterone, 11-deoxycortisol, Δ4-androstenedione, cortisol and cortisone in newborn blood spots using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:1565–72.CrossRefGoogle Scholar
  20. 20.
    Janzen N, Sander S, Terhardt M, Steuerwald U, Peter M, Das AM, et al. Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography–tandem mass spectrometry. Steroids. 2011;13:1437–42.CrossRefGoogle Scholar
  21. 21.
    USFDA 510(k) Substantial equivalence determination decision summary assay only template. https://www.accessdata.fda.gov/cdrh_docs/reviews/K081922.pdf. Accessed 17 Aug 2018.
  22. 22.
  23. 23.
    CDC Newborn Screening Quality Assurance Program, 2016 Quality Control Program Report. https://www.cdc.gov/labstandards/pdf/nsqap/nsqap_2016_qcset1_report.pdf. Accessed 17 Aug 2018.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Liqiao Han
    • 1
  • Norma P. Tavakoli
    • 2
  • Mark Morrissey
    • 2
  • David C. Spink
    • 2
  • Zhimin (Tim) Cao
    • 2
    • 3
    Email author
  1. 1.Department of Laboratory MedicineThe Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhouChina
  2. 2.New York State Department of HealthWadsworth CenterAlbanyUSA
  3. 3.College of Arts and SciencesUniversity at Albany, State University of New YorkAlbanyUSA

Personalised recommendations